Evaluation of ratioNally Designed Influenza vaccines

Project Information

ENDFLU

Grant agreement ID: 874650

DOI 10.3030/874650

EC signature date 12 December 2019

Start date 1 August 2020

End date 31 July 2025

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost € 14 444 867,50

EU contribution € 8 646 254,25

Coordinated by

STIFTUNG TIERAERZTLICHE HOCHSCHULE HANNOVER
Germany

Deliverables

Documents, reports (3)

Composition of the SAB

This deliverable consists of a report listing the names and contact details of the Scientific Advisory Board including their expertise and role

Humoral immunological assay package

This deliverable consists of a report describing the humoral immunological assay package and confirming its availability for implementation and use

Cellular immunological assay package

This deliverable consists of a report describing the cellular immunological assay package and confirming its availability for implementation and use

Other (1)

ENDFLU website

This deliverable consists of the online publishing of ENDFLU website

Publications

Peer reviewed articles (6)

Protective Efficacy of Recombinant Influenza Hemagglutinin Ectodomain Fusions.

Author(s): Nidhi Mittal; Nayanika Sengupta; Sameer Kumar Malladi; Poorvi Reddy; Madhuraj Bhat; R. S. Rajmani; Koen Sedeyn; Xavier Saelens; Somnath Dutta; Raghavan Varadarajan
Published in: Viruses, Vol 13, Iss 1710, p 1710 (2021), Issue 1, 2021, Page(s) 1710, ISSN 1999-4915
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/v13091710

Comparative Immunogenicity of Bacterially Expressed Soluble Trimers and Nanoparticle Displayed Influenza Hemagglutinin Stem Immunogens

Author(s): Uddipan Kar1† Sara Khaleeq1† Priyanka Garg1 Madhuraj Bhat2 Poorvi Reddy2 Venkada Subramanian Vignesh1 Aditya Upadhyaya2 Mili Das2 Ghadiyaram Chakshusmathi2 Suman Pandey2 Somnath Dutta1 Raghavan Varadarajan1*
Published in: Front. Immunol., 2022, ISSN 1664-3224
Publisher: Frontiers Media S.A.
DOI: 10.3389/fimmu.2022.890622

Intradermal Immunization of Soluble Influenza HA Derived from a Lethal Virus Induces High Magnitude and Breadth of Antibody Responses and Provides Complete Protection In Vivo

Author(s): Raj, Sneha, Preeti Vishwakarma, Shikha Saxena, Varun Kumar, Ritika Khatri, Amit Kumar, Mrityunjay Singh, Surbhi Mishra, Shailendra Asthana, Shubbir Ahmed, and et al.
Published in: Vaccines, Issue 11(4), 2023, Page(s) 780, ISSN 2078-2489
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/vaccines11040780

Biophysical Correlates of Enhanced Immunogenicity of a Stabilized Variant of the Receptor Binding Domain of SARS-CoV-2.

Author(s): Kawkab Kanjo, Gopinath Chattopadhyay, Sameer Kumar Malladi, Randhir Singh, Sowrabha Jayatheertha, and Raghavan Varadarajan*
Published in: J. Phys. Chem. B, 2023, ISSN 1520-5126
Publisher: American Chemical Society
DOI: 10.1021/acs.jpcb.2c07262

Newly Designed Poxviral Promoters to Improve Immunogenicity and Efficacy of MVA-NP Candidate Vaccines against Lethal Influenza Virus Infection in Mice

Author(s): Langenmayer, Martin C., Anna-Theresa Luelf-Averhoff, Lisa Marr, Sylvia Jany, Astrid Freudenstein, Silvia Adam-Neumair, Alina Tscherne, Robert Fux, Juan J. Rojas, Andreas Blutke, and et al.
Published in: Pathogens, Issue 12(7), 2023, Page(s) 867, ISSN 2078-2489
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pathogens12070867

Computational design of vaccine immunogens

Author(s): Karla M Castro, Andreas Scheck, Shuhao Xiao, Bruno E Correia
Published in: Current Opinion in Biotechnology, Issue 78, 2022, ISSN 0958-1669
Publisher: Elsevier BV
DOI: 10.1016/j.copbio.2022.102821

Non-peer reviewed articles (4)

Influenza vaccines: successes and continuing challenges

Author(s): Tanja Becker, Husni Elbahesh, Leslie A Reperant, Guus F Rimmelzwaan, Albert D M E Osterhaus
Published in: The Journal of Infectious Diseases, 2021, ISSN 1537-6613
Publisher: Oxford Academic
DOI: 10.1093/infdis/jiab269

In Vivo Therapy with M2e-Specific IgG Selects for an Influenza A Virus Mutant with Delayed Matrix Protein 2 Expression

Author(s): Silvie Van den Hoecke, Marlies Ballegeer, Bram Vrancken, Lei Deng, Emma R. Job, Kenny Roose, Bert Schepens, Lien Van Hoecke, Philippe Lemey, Xavier Saelens
Published in: mBio, 2021, ISSN 2150-7511
Publisher: ASM
DOI: 10.1128/mbio.00745-21

The identification of novel promoters and terminators for protein expression and metabolic engineering applications in Kluyveromyces marxianus

Author(s): Pradeep Kumar, Debendra Kumar Sahoo, Deepak Sharma
Published in: Metabolic Engineering Communications, 2021, ISSN 2214-0301
Publisher: Elsevier BV
DOI: 10.1016/j.mec.2020.e00160

Influenza Neuraminidase Characteristics and Potential as a Vaccine Target

Author(s): Sarah Creytens, Mirte N. Pascha, Marlies Ballegeer, Xavier Saelens and Cornelis A. M. de Haan
Published in: Frontiers in Immunology, 2021, ISSN 1664-3224
Publisher: International Union of Immunological Societies (IUIS)
DOI: 10.3389/fimmu.2021.786617

Book chapters (1)

Chapter 2 - Deep mutational scanning to probe specificity determinants in proteins

Author(s): Jayantika Bhowmick *, Soumyanetra Chandra *, Raghavan Varadarajan
Published in: Structure and Intrinsic Disorder in Enzymology, 2022, ISBN 978-0-323-99533-7
Publisher: Academic Press
DOI: 10.1016/b978-0-323-99533-7.00005-4

Conference proceedings (1)

Mosaic N1 and N2 neuraminidase nanoparticles induce high antibody titers and potent protection from Influenza A virus H1N1 and H3N2 challenge

Author(s): Mirte Pascha, Marlies Ballegeer, Irina Albulescu, Berend Jan Bosch, Frank J.M. van Kuppeveld, Xavier Saelens, Cornelis A.M. de Haan
Published in: 2022
Publisher: Zoonosen